Challenges and Future Trends in the Treatment of Psoriasis
Abstract
:1. Introduction
2. Current Treatment Guidelines
2.1. Treatments for Mild Psoriasis
2.2. Treatments for Moderate-to-Severe Psoriasis
2.2.1. Phototherapy
2.2.2. Oral Systemic Treatments
2.2.3. Biologics for the Treatment of Moderate-to-Severe Plaque Psoriasis
- TNF-α inhibitors
- IL-23 inhibitors
- IL-17 inhibitors
3. Challenges in the Current Treatment of Psoriasis
4. Future Aspects in the Treatment of Psoriasis
4.1. Biologic Agents and Small Molecule Inhibitors under Development
4.1.1. IL-23 Inhibitors
4.1.2. JAK Inhibitors
4.1.3. IL-36 Inhibitors
4.1.4. RORγt Inhibitors
4.1.5. ROCK2 Inhibitors
4.2. Advancements in Topical Treatments
4.2.1. Microneedles
4.2.2. Topical Nanocarriers
4.3. Biomarker Development and Application of Multi-Omics
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- World Health, O. Global Report on Psoriasis; World Health Organization: Geneva, Switzerland, 2016. [Google Scholar]
- Griffiths, C.E.M.; Armstrong, A.W.; Gudjonsson, J.E.; Barker, J. Psoriasis. Lancet 2021, 397, 1301–1315. [Google Scholar] [CrossRef]
- Armstrong, A.W.; Read, C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA 2020, 323, 1945–1960. [Google Scholar] [CrossRef]
- Kaushik, S.B.; Lebwohl, M.G. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J. Am. Acad. Dermatol. 2019, 80, 27–40. [Google Scholar] [CrossRef]
- Reid, C.; Griffiths, C.E.M. Psoriasis and Treatment: Past, Present and Future Aspects. Acta Derm.-Venereol. 2020, 100, adv00032. [Google Scholar] [CrossRef]
- Singh, A.; Easwari, T.S. Recent Advances in Psoriasis Therapy: Trends and Future Prospects. Curr. Drug Targets 2021, 22, 1760–1771. [Google Scholar] [CrossRef]
- Gyldenløve, M.; Alinaghi, F.; Zachariae, C.; Skov, L.; Egeberg, A. Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review. Am. J. Clin. Dermatol. 2022, 23, 605–613. [Google Scholar] [CrossRef]
- Hsieh, T.S.; Tsai, T.F. Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review. Dermatol. Ther. 2023, 13, 891–909. [Google Scholar] [CrossRef]
- Pourani, M.R.; Abdollahimajd, F.; Zargari, O.; Shahidi Dadras, M. Soluble biomarkers for diagnosis, monitoring, and therapeutic response assessment in psoriasis. J. Dermatol. Treat. 2022, 33, 1967–1974. [Google Scholar] [CrossRef]
- Lwin, S.M.; Snowden, J.A.; Griffiths, C.E.M. The promise and challenges of cell therapy for psoriasis. Br. J. Dermatol. 2021, 185, 887–898. [Google Scholar] [CrossRef]
- Salgado-Boquete, L.; Carrascosa, J.M.; Llamas-Velasco, M.; Ruiz-Villaverde, R.; de la Cueva, P.; Belinchón, I. A New Classification of the Severity of Psoriasis: What’s Moderate Psoriasis? Life 2021, 11, 627. [Google Scholar] [CrossRef]
- Mrowietz, U.; Kragballe, K.; Reich, K.; Spuls, P.; Griffiths, C.E.; Nast, A.; Franke, J.; Antoniou, C.; Arenberger, P.; Balieva, F.; et al. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch. Dermatol. Res. 2011, 303, 1–10. [Google Scholar] [CrossRef]
- Oranje, A.P.; Marcoux, D.; Svensson, A.; Prendiville, J.; Krafchik, B.; Toole, J.; Rosenthal, D.; de Waard-van der Spek, F.B.; Molin, L.; Axelsen, M. Topical calcipotriol in childhood psoriasis. J. Am. Acad. Dermatol. 1997, 36, 203–208. [Google Scholar] [CrossRef]
- Maul, J.T.; Anzengruber, F.; Conrad, C.; Cozzio, A.; Häusermann, P.; Jalili, A.; Kolios, A.G.A.; Laffitte, E.; Lapointe, A.K.; Mainetti, C.; et al. Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway. Dermatology 2021, 237, 166–178. [Google Scholar] [CrossRef]
- Elmets, C.A.; Korman, N.J.; Prater, E.F.; Wong, E.B.; Rupani, R.N.; Kivelevitch, D.; Armstrong, A.W.; Connor, C.; Cordoro, K.M.; Davis, D.M.R.; et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J. Am. Acad. Dermatol. 2021, 84, 432–470. [Google Scholar] [CrossRef]
- Blauvelt, A.; Leonardi, C.L.; Gooderham, M.; Papp, K.A.; Philipp, S.; Wu, J.J.; Igarashi, A.; Flack, M.; Geng, Z.; Wu, T.; et al. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020, 156, 649–658. [Google Scholar] [CrossRef]
- Gold, L.S.; Lebwohl, M.G.; Sugarman, J.L.; Pariser, D.M.; Lin, T.; Martin, G.; Pillai, R.; Israel, R.; Ramakrishna, T. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. J. Am. Acad. Dermatol. 2018, 79, 287–293. [Google Scholar] [CrossRef]
- Lis-Święty, A.; Frątczak, A. Proactive therapy: New perspectives for long-term topical treatment of psoriasis. Dermatol. Ther. 2022, 35, e15364. [Google Scholar] [CrossRef]
- Soleymani, T.; Hung, T.; Soung, J. The role of vitamin D in psoriasis: A review. Int. J. Dermatol. 2015, 54, 383–392. [Google Scholar] [CrossRef]
- Amiri, D.; Schwarz, C.W.; Gether, L.; Skov, L. Safety and Efficacy of Topical Calcineurin Inhibitors in the Treatment of Facial and Genital Psoriasis: A Systematic Review. Acta Derm.-Venereol. 2023, 103, adv00890. [Google Scholar] [CrossRef]
- Fritz, K.; Salavastru, C. The 308 nm Excimer laser for the treatment of psoriasis and inflammatory skin diseases. Der Hautarzt Z. Dermatol. Venerol. Verwandte Geb. 2018, 69, 35–43. [Google Scholar]
- Menter, A.; Strober, B.E.; Kaplan, D.H.; Kivelevitch, D.; Prater, E.F.; Stoff, B.; Armstrong, A.W.; Connor, C.; Cordoro, K.M.; Davis, D.M.R.; et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J. Am. Acad. Dermatol. 2019, 80, 1029–1072. [Google Scholar] [CrossRef]
- Menter, A.; Gelfand, J.M.; Connor, C.; Armstrong, A.W.; Cordoro, K.M.; Davis, D.M.R.; Elewski, B.E.; Gordon, K.B.; Gottlieb, A.B.; Kaplan, D.H.; et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J. Am. Acad. Dermatol. 2020, 82, 1445–1486. [Google Scholar] [CrossRef]
- Elmets, C.A.; Lim, H.W.; Stoff, B.; Connor, C.; Cordoro, K.M.; Lebwohl, M.; Armstrong, A.W.; Davis, D.M.R.; Elewski, B.E.; Gelfand, J.M.; et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J. Am. Acad. Dermatol. 2019, 81, 775–804. [Google Scholar] [CrossRef]
- Lambert, J.L.W.; Segaert, S.; Ghislain, P.D.; Hillary, T.; Nikkels, A.; Willaert, F.; Lambert, J.; Speeckaert, R. Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1). J. Eur. Acad. Dermatol. Venereol. JEADV 2020, 34, 1654–1665. [Google Scholar] [CrossRef]
- Armstrong, A.W.; Puig, L.; Joshi, A.; Skup, M.; Williams, D.; Li, J.; Betts, K.A.; Augustin, M. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. JAMA Dermatol. 2020, 156, 258–269. [Google Scholar] [CrossRef]
- Kimball, A.B.; Rothman, K.J.; Kricorian, G.; Pariser, D.; Yamauchi, P.S.; Menter, A.; Teller, C.F.; Aras, G.; Accortt, N.A.; Hooper, M.; et al. OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. J. Am. Acad. Dermatol. 2015, 72, 115–122. [Google Scholar] [CrossRef]
- Menter, A.; Thaçi, D.; Wu, J.J.; Abramovits, W.; Kerdel, F.; Arikan, D.; Guo, D.; Ganguli, A.; Bereswill, M.; Camez, A.; et al. Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry. Dermatol. Ther. 2017, 7, 365–381. [Google Scholar] [CrossRef]
- Kalb, R.E.; Fiorentino, D.F.; Lebwohl, M.G.; Toole, J.; Poulin, Y.; Cohen, A.D.; Goyal, K.; Fakharzadeh, S.; Calabro, S.; Chevrier, M.; et al. Risk of Serious Infection with Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015, 151, 961–969. [Google Scholar] [CrossRef]
- Poulin, Y.; Thérien, G. Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: Case report and literature review. J. Cutan. Med. Surg. 2010, 14, 100–104. [Google Scholar] [CrossRef]
- López-Ferrer, A.; Vilarrasa, E.; Puig, L. Secukinumab (AIN457) for the treatment of psoriasis. Expert Rev. Clin. Immunol. 2015, 11, 1177–1188. [Google Scholar] [CrossRef]
- Papp, K.A.; Leonardi, C.L.; Blauvelt, A.; Reich, K.; Korman, N.J.; Ohtsuki, M.; Paul, C.; Ball, S.; Cameron, G.S.; Erickson, J.; et al. Ixekizumab treatment for psoriasis: Integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br. J. Dermatol. 2018, 178, 674–681. [Google Scholar] [CrossRef]
- Foulkes, A.C.; Warren, R.B. Brodalumab in psoriasis: Evidence to date and clinical potential. Drugs Context 2019, 8, 212570. [Google Scholar] [CrossRef]
- Reich, K.; Leonardi, C.; Langley, R.G.; Warren, R.B.; Bachelez, H.; Romiti, R.; Ohtsuki, M.; Xu, W.; Acharya, N.; Solotkin, K.; et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J. Am. Acad. Dermatol. 2017, 76, 441–448.E2. [Google Scholar] [CrossRef] [PubMed]
- Dávila-Seijo, P.; Dauden, E.; Descalzo, M.A.; Carretero, G.; Carrascosa, J.M.; Vanaclocha, F.; Gómez-García, F.J.; De la Cueva-Dobao, P.; Herrera-Ceballos, E.; Belinchón, I.; et al. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the Biobadaderm Registry. J. Investig. Dermatol. 2017, 137, 313–321. [Google Scholar] [CrossRef]
- Beck, K.M.; Koo, J. Brodalumab for the treatment of plaque psoriasis: Up-to-date. Expert Opin. Biol. Ther. 2019, 19, 287–292. [Google Scholar] [CrossRef]
- Puig, L. Induction phase, primary endpoint, time to decide on primary failure, and therapeutic goals in biologic treatment of psoriasis. J. Eur. Acad. Dermatol. Venereol. JEADV 2013, 27, e257–e260. [Google Scholar] [CrossRef]
- Hazlewood, G.S.; Barnabe, C.; Tomlinson, G.; Marshall, D.; Devoe, D.J.; Bombardier, C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. Cochrane Database Syst. Rev. 2016, 2016, Cd010227. [Google Scholar] [CrossRef]
- Cather, J.C.; Crowley, J.J. Use of biologic agents in combination with other therapies for the treatment of psoriasis. Am. J. Clin. Dermatol. 2014, 15, 467–478. [Google Scholar] [CrossRef]
- Ormerod, A.D. Switching biologics for psoriasis. Br. J. Dermatol. 2010, 163, 667–669. [Google Scholar] [CrossRef]
- Özkur, E.; Kıvanç Altunay, İ.; Oğuz Topal, İ.; Aytekin, S.; Topaloğlu Demir, F.; Özkök Akbulut, T.; Kara Polat, A.; Karadağ, A.S. Switching Biologics in the Treatment of Psoriasis: A Multicenter Experience. Dermatology 2021, 237, 22–30. [Google Scholar] [CrossRef]
- Honda, H.; Umezawa, Y.; Kikuchi, S.; Yanaba, K.; Fukuchi, O.; Ito, T.; Nobeyama, Y.; Asahina, A.; Nakagawa, H. Switching of biologics in psoriasis: Reasons and results. J. Dermatol. 2017, 44, 1015–1019. [Google Scholar] [CrossRef]
- Armstrong, A.W.; Patel, M.; Li, C.; Garg, V.; Mandava, M.R.; Wu, J.J. Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States. J. Dermatol. Treat. 2023, 34, 2200870. [Google Scholar] [CrossRef]
- Shin, J.O.; Seok Shin, B.; Bae, K.N.; Shin, K.; Kim, H.S.; Ko, H.C.; Kim, M.B.; Kim, B. Review of the reasons for and effectiveness of switching biologics for psoriasis treatment in Korea. Indian J. Dermatol. Venereol. Leprol. 2023, 28, 1–6. [Google Scholar] [CrossRef]
- Porter, C.; Woods, A.; Mendelow, M.; Purvis, C.; Feldman, S. Unmet Needs in Psoriasis Patients. J. Drugs Dermatol. JDD 2022, 21, 839–844. [Google Scholar] [CrossRef]
- Egeberg, A.; Ottosen, M.B.; Gniadecki, R.; Broesby-Olsen, S.; Dam, T.N.; Bryld, L.E.; Rasmussen, M.K.; Skov, L. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br. J. Dermatol. 2018, 178, 509–519. [Google Scholar] [CrossRef] [PubMed]
- García-Beloso, N.; Altabás-González, I.; Samartín-Ucha, M.; Gayoso-Rey, M.; De Castro-Parga, M.L.; Salgado-Barreira, Á.; Cibeira-Badia, A.; Piñeiro-Corrales, M.G.; González-Vilas, D.; Pego-Reigosa, J.M.; et al. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review. Br. J. Clin. Pharmacol. 2022, 88, 1529–1550. [Google Scholar] [CrossRef]
- Ghafoor, R.; Patil, A.; Yamauchi, P.; Weinberg, J.; Kircik, L.; Grabbe, S.; Goldust, M. Treatment of Scalp Psoriasis. J. Drugs Dermatol. JDD 2022, 21, 833–837. [Google Scholar] [CrossRef] [PubMed]
- Thomas, L.; Azad, J.; Takwale, A. Management of nail psoriasis. Clin. Exp. Dermatol. 2021, 46, 3–8. [Google Scholar] [CrossRef]
- Kelly, A.; Ryan, C. Genital Psoriasis: Impact on Quality of Life and Treatment Options. Am. J. Clin. Dermatol. 2019, 20, 639–646. [Google Scholar] [CrossRef]
- Misiak-Galazka, M.; Zozula, J.; Rudnicka, L. Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments. Am. J. Clin. Dermatol. 2020, 21, 355–370. [Google Scholar] [CrossRef] [PubMed]
- Hoegler, K.M.; John, A.M.; Handler, M.Z.; Schwartz, R.A. Generalized pustular psoriasis: A review and update on treatment. J. Eur. Acad. Dermatol. Venereol. JEADV 2018, 32, 1645–1651. [Google Scholar] [CrossRef] [PubMed]
- Blauvelt, A.; Kimball, A.B.; Augustin, M.; Okubo, Y.; Witte, M.M.; Capriles, C.R.; Sontag, A.; Arora, V.; Osuntokun, O.; Strober, B. Efficacy and safety of mirikizumab in psoriasis: Results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1). Br. J. Dermatol. 2022, 187, 866–877. [Google Scholar] [CrossRef]
- Krueger, J.G.; McInnes, I.B.; Blauvelt, A. Tyrosine kinase 2 and Janus kinase–signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J. Am. Acad. Dermatol. 2022, 86, 148–157. [Google Scholar] [CrossRef]
- Zhang, L.; Guo, L.; Wang, L.; Jiang, X. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis—A network meta-analysis. J. Eur. Acad. Dermatol. Venereol. JEADV 2022, 36, 1937–1946. [Google Scholar] [CrossRef]
- Strober, B.; Thaçi, D.; Sofen, H.; Kircik, L.; Gordon, K.B.; Foley, P.; Rich, P.; Paul, C.; Bagel, J.; Colston, E.; et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for Evaluation of TYK2 inhibitor psoriasis second trial. J. Am. Acad. Dermatol. 2023, 88, 40–51. [Google Scholar] [CrossRef]
- Madonna, S.; Girolomoni, G.; Dinarello, C.A.; Albanesi, C. The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis. Int. J. Mol. Sci. 2019, 20, 3318. [Google Scholar] [CrossRef]
- Hussain, S.; Berki, D.M.; Choon, S.E.; Burden, A.D.; Allen, M.H.; Arostegui, J.I.; Chaves, A.; Duckworth, M.; Irvine, A.D.; Mockenhaupt, M.; et al. IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J. Allergy Clin. Immunol. 2015, 135, 1067–1070.e1069. [Google Scholar] [CrossRef]
- Todorović, V.; Su, Z.; Putman, C.B.; Kakavas, S.J.; Salte, K.M.; McDonald, H.A.; Wetter, J.B.; Paulsboe, S.E.; Sun, Q.; Gerstein, C.E.; et al. Small Molecule IL-36γ Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis. Sci. Rep. 2019, 9, 9089. [Google Scholar] [CrossRef]
- Ali, F.; Smith, C.H.; Mahil, S.K. Spesolimab in the treatment of generalized pustular psoriasis: A critically appraised research paper. Br. J. Dermatol. 2023, 188, 328–329. [Google Scholar] [CrossRef]
- Conti, P.; Pregliasco, F.E.; Bellomo, R.G.; Gallenga, C.E.; Caraffa, A.; Kritas, S.K.; Lauritano, D.; Ronconi, G. Mast Cell Cytokines IL-1, IL-33, and IL-36 Mediate Skin Inflammation in Psoriasis: A Novel Therapeutic Approach with the Anti-Inflammatory Cytokines IL-37, IL-38, and IL-1Ra. Int. J. Mol. Sci. 2021, 22, 8076. [Google Scholar] [CrossRef]
- Tang, L.; Yang, X.; Liang, Y.; Xie, H.; Dai, Z.; Zheng, G. Transcription Factor Retinoid-Related Orphan Receptor γt: A Promising Target for the Treatment of Psoriasis. Front. Immunol. 2018, 9, 1210. [Google Scholar] [CrossRef] [PubMed]
- Pandya, V.B.; Kumar, S.; Sachchidanand; Sharma, R.; Desai, R.C. Combating Autoimmune Diseases with Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ or RORc) Inhibitors: Hits and Misses. J. Med. Chem. 2018, 61, 10976–10995. [Google Scholar] [CrossRef]
- Zanin-Zhorov, A.; Weiss, J.M.; Trzeciak, A.; Chen, W.; Zhang, J.; Nyuydzefe, M.S.; Arencibia, C.; Polimera, S.; Schueller, O.; Fuentes-Duculan, J.; et al. Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10. J. Immunol. 2017, 198, 3809–3814. [Google Scholar] [CrossRef]
- Chen, A.; Luo, Y.; Xu, J.; Guan, X.; He, H.; Xuan, X.; Wu, J. Latest on biomaterial-based therapies for topical treatment of psoriasis. J. Mater. Chem. B 2022, 10, 7397–7417. [Google Scholar] [CrossRef] [PubMed]
- Yang, D.; Chen, M.; Sun, Y.; Jin, Y.; Lu, C.; Pan, X.; Quan, G.; Wu, C. Microneedle-mediated transdermal drug delivery for treating diverse skin diseases. Acta Biomater. 2021, 121, 119–133. [Google Scholar] [CrossRef] [PubMed]
- Prausnitz, M.R.; Langer, R. Transdermal drug delivery. Nat. Biotechnol. 2008, 26, 1261–1268. [Google Scholar] [CrossRef] [PubMed]
- Lee, J.H.; Jung, Y.S.; Kim, G.M.; Bae, J.M. A hyaluronic acid-based microneedle patch to treat psoriatic plaques: A pilot open trial. Br. J. Dermatol. 2018, 178, e24–e25. [Google Scholar] [CrossRef]
- Du, H.; Liu, P.; Zhu, J.; Lan, J.; Li, Y.; Zhang, L.; Zhu, J.; Tao, J. Hyaluronic Acid-Based Dissolving Microneedle Patch Loaded with Methotrexate for Improved Treatment of Psoriasis. ACS Appl. Mater. Interfaces 2019, 11, 43588–43598. [Google Scholar] [CrossRef]
- Wan, T.; Pan, Q.; Ping, Y. Microneedle-assisted genome editing: A transdermal strategy of targeting NLRP3 by CRISPR-Cas9 for synergistic therapy of inflammatory skin disorders. Sci. Adv. 2021, 7, eabe2888. [Google Scholar] [CrossRef]
- Carter, P.; Narasimhan, B.; Wang, Q. Biocompatible nanoparticles and vesicular systems in transdermal drug delivery for various skin diseases. Int. J. Pharm. 2019, 555, 49–62. [Google Scholar] [CrossRef]
- Abdelbary, A.A.; AbouGhaly, M.H. Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: Application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study. Int. J. Pharm. 2015, 485, 235–243. [Google Scholar] [CrossRef] [PubMed]
- Bessar, H.; Venditti, I.; Benassi, L.; Vaschieri, C.; Azzoni, P.; Pellacani, G.; Magnoni, C.; Botti, E.; Casagrande, V.; Federici, M.; et al. Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis. Colloids Surf. B Biointerfaces 2016, 141, 141–147. [Google Scholar] [CrossRef]
- Özcan, A.; Sahin, D.; Impellizzieri, D.; Nguyen, T.T.; Hafner, J.; Yawalkar, N.; Kurzbach, D.; Tan, G.; Akdis, C.A.; Nilsson, J.; et al. Nanoparticle-Coupled Topical Methotrexate Can Normalize Immune Responses and Induce Tissue Remodeling in Psoriasis. J. Investig. Dermatol. 2020, 140, 1003–1014.e1008. [Google Scholar] [CrossRef] [PubMed]
- Crisan, D.; Scharffetter-Kochanek, K.; Crisan, M.; Schatz, S.; Hainzl, A.; Olenic, L.; Filip, A.; Schneider, L.A.; Sindrilaru, A. Topical silver and gold nanoparticles complexed with Cornus mas suppress inflammation in human psoriasis plaques by inhibiting NF-κB activity. Exp. Dermatol. 2018, 27, 1166–1169. [Google Scholar] [CrossRef] [PubMed]
- Gomez, C.; Muangnoi, C.; Sorasitthiyanukarn, F.N.; Wongpiyabovorn, J.; Rojsitthisak, P.; Rojsitthisak, P. Synergistic Effects of Photo-Irradiation and Curcumin-Chitosan/Alginate Nanoparticles on Tumor Necrosis Factor-Alpha-Induced Psoriasis-Like Proliferation of Keratinocytes. Molecules 2019, 24, 1388. [Google Scholar] [CrossRef]
- Shores, L.S.; Kelly, S.H.; Hainline, K.M.; Suwanpradid, J.; MacLeod, A.S.; Collier, J.H. Multifactorial Design of a Supramolecular Peptide Anti-IL-17 Vaccine Toward the Treatment of Psoriasis. Front. Immunol. 2020, 11, 1855. [Google Scholar] [CrossRef]
- Kumar, L.; Verma, S.; Joshi, K.; Utreja, P.; Sharma, S. Nanofiber as a novel vehicle for transdermal delivery of therapeutic agents: Challenges and opportunities. Future J. Pharm. Sci. 2021, 7, 175. [Google Scholar] [CrossRef]
- Ramessur, R.; Corbett, M.; Marshall, D.; Acencio, M.L.; Barbosa, I.A.; Dand, N.; Di Meglio, P.; Haddad, S.; Jensen, A.H.M.; Koopmann, W.; et al. Biomarkers of disease progression in people with psoriasis: A scoping review. Br. J. Dermatol. 2022, 187, 481–493. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lee, H.-J.; Kim, M. Challenges and Future Trends in the Treatment of Psoriasis. Int. J. Mol. Sci. 2023, 24, 13313. https://doi.org/10.3390/ijms241713313
Lee H-J, Kim M. Challenges and Future Trends in the Treatment of Psoriasis. International Journal of Molecular Sciences. 2023; 24(17):13313. https://doi.org/10.3390/ijms241713313
Chicago/Turabian StyleLee, Hyun-Ji, and Miri Kim. 2023. "Challenges and Future Trends in the Treatment of Psoriasis" International Journal of Molecular Sciences 24, no. 17: 13313. https://doi.org/10.3390/ijms241713313